KINGSEY FALLS, QC, May 7, 2026 /PRNewswire/ - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended March 31, 2026.
Q1 2026 Highlights
- Sales of $1,125 million (compared with $1,197 million in Q4 2025 and $1,154 million in Q1 2025);
- Operating income of $81 million (compared with $76 million in Q4 2025 and $50 million in Q1 2025);
- Net earnings per common share of $0.38 (compared with $0.37 in Q4 2025 and $0.07 in Q1 2025);
- Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A)1) of $118 million (compared with $155 million in Q4 2025 and $125 million in Q1 2025);
- Adjusted net earnings per common share1 of $0.07 (compared with $0.40 in Q4 2025 and $0.13 in Q1 2025);
- Net debt1 of $1,901 million as of March 31, 2026 (compared with $1,896 million as of December 31, 2025). Net debt to EBITDA (A) ratio1 remained stable at 3.3x;
- Total capital expenditures of $28 million in Q1 2026, compared to $42 million in Q4 2025 and $36 million in Q1 2025. The Corporation's 2026 forecasted capital expenditures before disposals will be in a range of $150 million to $175 million.
- The Company generated $91 million in asset sale proceeds during the first quarter, bringing total proceeds to $149 million for the 2025 - 2026 period. The Company's objective of generating $230 million is progressing well and is expected to be achieved by the end of third quarter of 2026.
Hugues Simon, President and CEO, commented: "First quarter results came in below our initial forecast, reflecting equally weighted external and operational factors. As disclosed in our revised outlook on April?10, weather?related disruptions across the U.S., combined with heightened volatility in transportation and fuel costs, drove operating costs above plan. Additionally, recent geopolitical developments weighed on consumer confidence and spending, resulting in packaging volumes below our original assumptions. Performance was further impacted by temporary execution inefficiencies in the second half of the quarter. Despite this, net debt remained stable sequentially, and the leverage ratio was unchanged at 3.3x."
Discussing near-term outlook, Mr. Simon commented, "We expect results in the second quarter to be modestly lower sequentially. This outlook reflects a cautious packaging volume outlook amid restrained consumer spending levels, as well as continued volatility and upward pressure on input costs. The implementation of announced price increases in both segments is expected to fully offset these headwinds, with pricing actions taking effect in packaging beginning in the second quarter and during the second half of the year in tissue.
Amid the dynamic macro-economic environment we have strengthened our execution discipline to achieve our objective of generating $100 million of profitability improvements by the end of 2026. Key drivers include ongoing cost reduction initiatives, logistics optimization, productivity efficiency enhancements and targeted pricing actions to mitigate significant cost headwinds. We expect to achieve our target of proceeds from the sale of non-core assets by the end of the third quarter, and continue to actively review our portfolio of assets to ensure strong alignment with the Company's long-term strategic objectives. Given persistent cost pressures in the first half of 2026, annual results are currently expected to be below 2025 levels; however countermeasures, including selling price initiatives, that are currently underway are projected to restore annual run rate adjusted EBITDA (A)1 to a level of approximately $600 million in the second half of the year. In this context, achieving our targeted leverage ratio of 2.5x-3.0x by year-end may be challenging, though the target remains unchanged."
1 Some information represents non-IFRS Accounting Standards Financial measures, other financial measures or non-IFRS Accounting Standards ratios which are not standardized under IFRS Accounting Standards and therefore might not be comparable to similar financial measures disclosed by other corporations. Please refer to the "Supplemental Information on Non-IFRS Accounting Standards
Measures and Other Financial Measures" section for a complete reconciliation.
Financial Summary
Selected consolidated information
(in millions of Canadian dollars, except amounts per common share) (unaudited) Q1 2026 Q4 2025 Q1 2025
Sales 1,125 1,197 1,154
As Reported
Operating income 81 76 50
Net earnings 39 37 7
per common share (basic) $0.38 $0.37 $0.07
Adjusted
(1)
Earnings before interest, taxes, depreciation and amortization (EBITDA (A)) 118 155 125
Net earnings 7 40 13
per common share (basic) $0.07 $0.40 $0.13
Margin (EBITDA (A) / Sales) 10.5 % 12.9 % 10.8 %
Net debt
(1) 1,901 1,896 2,216
Net debt / EBITDA (A) ratio
(1) 3.3x 3.3x 4.2x
Segmented sales
(in millions of Canadian dollars) (unaudited) Q1 2026 Q4 2025 Q1 2025
Packaging Products 715 757 762
Tissue Papers 380 407 364
Inter-segment sales, Corporate, Recovery and Recycling activities 30 33 28
Sales 1,125 1,197 1,154
Segmented operating income (loss)
(in millions of Canadian dollars) (unaudited) Q1 2026 Q4 2025 Q1 2025
Packaging Products 88 90 60
Tissue Papers 20 14 24
Corporate, Recovery and Recycling activities (27) (28) (34)
Operating income 81 76 50
Segmented EBITDA (A)1
(in millions of Canadian dollars) (unaudited) Q1 2026 Q4 2025 Q1 2025
Packaging Products 103 132 109
Tissue Papers 33 42 37
Corporate, Recovery and Recycling activities (18) (19) (21)
EBITDA (A)
(1) 118 155 125
1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.
Analysis of results for the three-month period ended March31,2026 (compared to the same period last year)
The Corporation's first quarter sales of $1,125 million decreased by $29 million compared with the same period last year. This decrease reflects consolidated net benefits of $18 million from higher selling prices and a favourable sales mix of $21 million. However, these factors were more than offset by an unfavourable foreign exchange rate of $33 million and by a $35 million impact from lower volumes, mainly in the Packaging Products segment, reflecting the impact of business closures and dispositions.
The first quarter EBITDA (A)1 totaled $118 million, a decrease of $7 million, or 6%, from the $125 million generated in the same period last year. This decrease was driven by higher logistics, production and energy costs across the Corporation's businesses, and lower volumes in the Packaging Products segment. These impacts were partially offset by the benefits from higher selling prices and lower raw material costs.
The main specific items, before income taxes, that impacted our first quarter of 2026 operating income and/or net earnings were:
- $8 million of impairment on a building and equipment related to a previously closed plant in the United States (operating income and net earnings);
- $49 million of gains related to the sale of a business and some assets in Canada (operating income and net earnings);
- $3 million of restructuring costs related to plants closure in Canada and in the United States and corporate organizational changes (operating income and net earnings);
- $4 million loss on financial instruments (operating income and net earnings).
For the three-month period ended March 31, 2026, the Corporation posted net earnings of $39 million, or $0.38 per common share, compared to net earnings of $7 million, or $0.07 per common share, in the same period of 2025. On an adjusted basis1, the Corporation posted net earnings of $7 million in the first quarter of 2026, or $0.07 per common share, compared to net earnings of $13 million, or $0.13 per common share, in the same period of 2025.
1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.
Dividend on common shares and normal course issuer bid
The Board of Directors of Cascades declared a quarterly dividend of $0.12 per common share to be paid on June 4, 2026 to shareholders of record at the close of business on May 21, 2026. This dividend is an "eligible dividend" as per the Income Tax Act (R.C.S. (1985), Canada). During the first quarter of 2026, Cascades purchased no common shares for cancellation.
2026 First Quarter Results Conference Call Details
Management will discuss the 2026 first quarter financial results during a conference call today at 9:00 a.m. ET. The call can be accessed by dialing 1-800-990-4777 (international 1-289-819-1299). The conference call, including the investor presentation, will be broadcast live on the Cascades website (www.cascades.com) under the "Investors" section. A replay of the call will be available on the Cascades website and may also be accessed by phone until June 7, 2026 by dialing 1-888-660-6345 (international 1-289-819-1450), access code 49689 #.
Founded in 1964, Cascades offers sustainable, innovative and value-added packaging, hygiene and recovery solutions. The company employs approximately 8,800women and men across a network of 61 operating facilities, including 17 Recovery and Recycling facilities which are part of Corporate Activities and joint ventures managed by the Corporation, in North America. Driven by its participative management, half a century of experience in recycling, and continuous research and development efforts, Cascades continues to provide innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS. Certain statements in this release, including statements regarding future results and performance, are forward-looking statements based on current expectations. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those projected, including, but not limited to, the effect of general economic conditions, decreases in demand for the Corporation's products, increases in raw material costs, fluctuations in selling prices and adverse changes in general market and industry conditions and otherfactors.
CONSOLIDATED BALANCE SHEETS
(in millions of Canadian dollars) (unaudited) March 31, December 31,
2026 2025
Assets
Current assets
Cash and cash equivalents 85 48
Accounts receivable 444 426
Current income tax assets 12 12
Inventories 681 661
Current portion of financial assets 4 4
1,226 1,151
Long-term assets
Investments in associates and joint ventures 68 66
Property, plant and equipment 2,633 2,649
Intangible assets with finite useful life 30 30
Financial assets 3 5
Other assets 107 107
Deferred income tax assets 180 174
Goodwill and other intangible assets with indefinite useful life 495 491
4,742 4,673
Liabilities and Equity
Current liabilities
Trade and other payables 685 697
Current income tax liabilities 4 4
Current portion of long-term debt 78 70
Current portion of provisions for charges 7 8
Current portion of financial liabilities and other liabilities 28 28
802 807
Long-term liabilities
Long-term debt 1,908 1,874
Provisions for charges 58 58
Financial liabilities 11 8
Other liabilities 69 74
Deferred income tax liabilities 101 97
2,949 2,918
Equity
Capital stock 619 619
Contributed surplus 18 17
Retained earnings 1,069 1,042
Accumulated other comprehensive income 51 43
Equity attributable to Shareholders 1,757 1,721
Non-controlling interests 36 34
Total equity 1,793 1,755
4,742 4,673
CONSOLIDATED STATEMENTS OF EARNINGS
For the 3-month periods
ended March 31,
(in millions of Canadian dollars, except per common share amounts and number of common shares) (unaudited) 2026 2025
Sales 1,125 1,154
Supply chain and logistics 679 679
Wages and employee benefits expenses 266 280
Depreciation and amortization 71 69
Maintenance and repair 60 64
Other operational costs 2 6
Impairment charges 8 1
Other loss (gain) (49) 4
Restructuring costs 3 5
Loss (gain) on derivative financial instruments 4 (4)
Operating income 81 50
Financing expenses 31 36
Share of results of associates and joint ventures (2) (3)
Earnings before income taxes 52 17
Provision for income taxes 8 5
Net earnings including non-controlling interests for the period 44 12
Net earnings attributable to non-controlling interests 5 5
Net earnings attributable to Shareholders for the period 39 7
Net earnings per common share
Basic $0.38 $0.07
Diluted $0.38 $0.07
Weighted average basic number of common shares outstanding 101,283,722 100,993,811
Weighted average number of diluted common shares 102,033,598 101,421,656
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the 3-month periods
ended March 31,
(in millions of Canadian dollars) (unaudited) 2026 2025
Net earnings including non-controlling interests for the period 44 12
Other comprehensive income (loss)
Items that may be reclassified subsequently to earnings
Translation adjustments
Change in foreign currency translation of foreign subsidiaries 15 (41)
Change in foreign currency translation related to net investment hedging activities (7) 40
Recovery of income taxes 1
9 (1)
Items that are not released to earnings
Actuarial loss on employee future benefits (1)
Other comprehensive income (loss) 9 (2)
Comprehensive income including non-controlling interests for the period 53 10
Comprehensive income attributable to non-controlling interests for the period 6 5
Comprehensive income attributable to Shareholders for the period 47 5
CONSOLIDATED STATEMENTS OF EQUITY
For the 3-month period ended March 31, 2026
(in millions of Canadian dollars) (unaudited) CAPITAL STOCK CONTRIBUTED RETAINED ACCUMULATED TOTAL EQUITY NON- TOTAL EQUITY
SURPLUS EARNINGS OTHER ATTRIBUTABLE TO CONTROLLING
COMPREHENSIVE SHAREHOLDERS INTERESTS
INCOME
Balance - Beginning of period 619 17 1,042 43 1,721 34 1,755
Comprehensive income
Net earnings 39 39 5 44
Other comprehensive income 8 8 1 9
39 8 47 6 53
Dividends (12) (12) (4) (16)
Stock options expense 1 1 1
Balance - End of period 619 18 1,069 51 1,757 36 1,793
For the 3-month period ended March 31, 2025
(in millions of Canadian dollars) (unaudited) CAPITAL STOCK CONTRIBUTED RETAINED ACCUMULATED TOTAL EQUITY NON- TOTAL EQUITY
SURPLUS EARNINGS OTHER ATTRIBUTABLE TO CONTROLLING
COMPREHENSIVE SHAREHOLDERS INTERESTS
INCOME
Balance - Beginning of period 616 16 1,019 73 1,724 47 1,771
Comprehensive income (loss)
Net earnings 7 7 5 12
Other comprehensive income (loss) (1) (1) (2) (2)
6 (1) 5 5 10
Dividends (12) (12) (3) (15)
Issuance of common shares upon exercise of stock options 1 1 1
Balance - End of period 617 16 1,013 72 1,718 49 1,767
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the 3-month periods
ended March 31,
(in millions of Canadian dollars) (unaudited) 2026 2025
Operating activities
Net earnings attributable to Shareholders for the period 39 7
Adjustments for:
Financing expenses 31 36
Depreciation and amortization 71 69
Impairment charges 8 1
Other loss (gain) (49) 4
Restructuring costs 3 5
Loss (gain) on derivative financial instruments 4 (4)
Provision for income taxes 8 5
Share of results of associates and joint ventures (2) (3)
Net earnings attributable to non-controlling interests 5 5
Net financing expenses paid (52) (49)
Net income taxes paid (4) (2)
Payments, net of provisions, for charges and other liabilities, and other non-cash items (6) (29)
56 45
Changes in non-cash working capital components (38) (97)
18 (52)
Investing activities
Payments for property, plant and equipment (28) (36)
Proceeds from disposals of property, plant and equipment 31
Change in intangible and other assets (1) 1
Proceeds from business disposal 60
62 (35)
Financing activities
Bank loans and advances (6)
Change in credit facilities (2) 303
Change in credit facilities without recourse to the Corporation (4) 1
Repurchase of unsecured senior notes (175)
Payments of other long-term debt, including lease obligations (2026 - $21 million for the 3-month period; 2025 - (21) (19)
$18 million for the 3-month period)
Issuance of common shares upon exercise of stock options 1
Dividends paid to non-controlling interests (4) (3)
Dividends paid to the Corporation's Shareholders (12) (12)
(43) 90
Net change in cash and cash equivalents during the period 37 3
Currency translation on cash and cash equivalents (1)
Cash and cash equivalents - Beginning of the period 48 27
Cash and cash equivalents - End of the period 85 29
SEGMENTED INFORMATION
The Corporation's operations are managed in two segments: Packaging Products and Tissue Papers. The accounting policies of the reportable segments are the same as the Corporation's accounting policies described in the most recent Audited Consolidated Financial Statements for the year ended December 31, 2025.
The Corporation's operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The Chief Executive Officer has authority for resource allocation and management of the Corporation's performance and is therefore the CODM. The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)). The CODM considers EBITDA (A) to be the best performance measure of the Corporation's activities.
Sales for each segment are prepared on the same basis as those of the Corporation. Inter-segment operations are recorded on the same basis as sales to third parties, which are at fair market value.
EBITDA (A) does not have a standardized meaning under IFRS Accounting Standards; accordingly, it may not be comparable to similarly named measures used by other companies. Investors should not view EBITDA (A) as an alternative measure to, for example, net earnings, or as a measure of operating results, which are IFRS Accounting Standards measures.
Sales by business segment are shown in the following table:
SALES
For the 3-month periods ended March 31 2026 2025
(in millions of Canadian dollars) (unaudited)
Total Inter- External Total Inter-
segment segment External
Packaging Products 715 (6) 709 762 (13) 749
Tissue Papers 380 380 364 364
Corporate, Recovery and Recycling activities 62 (26) 36 73 (32) 41
1,157 (32) 1,125 1,199 (45) 1,154
EBITDA (A) by business segment is reconciled to the IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:
For the 3-month period ended March 31, 2026
(in millions of Canadian dollars) (unaudited) Packaging Tissue Papers Corporate, Consolidated
Products Recovery and
Recycling
activities
Operating income (loss) 88 20 (27) 81
Depreciation and amortization 49 13 9 71
Impairment charges 8 8
Other gain (47) (2) (49)
Restructuring costs 1 2 3
Loss on derivative financial instruments 4 4
EBITDA (A) 103 33 (18) 118
Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss) 568 327 50 945
For the 3-month period ended March 31, 2025
(in millions of Canadian dollars) (unaudited) Packaging Tissue Papers Corporate, Consolidated
Products Recovery and
Recycling
activities
Operating income (loss) 60 24 (34) 50
Depreciation and amortization 46 13 10 69
Impairment charges 1 1
Other loss 4 4
Restructuring costs 1 4 5
Gain on derivative financial instruments (2) (2) (4)
EBITDA (A) 109 37 (21) 125
Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss) 603 304 52 959
Payments for property, plant and equipment by business segment are shown in the following table:
PAYMENTS FOR PROPERTY, PLANT AND
EQUIPMENT
For the 3-month periods
ended March 31,
(in millions of Canadian dollars) (unaudited) 2026 2025
Packaging Products 46 34
Tissue Papers 7 8
Corporate, Recovery and Recycling activities 16 6
Total acquisitions 69 48
Right-of-use assets acquisitions and provisions (non-cash) (45) (24)
24 24
Acquisitions for property, plant and equipment included in "Trade and other payables"
Beginning of the period 17 32
End of the period (13) (20)
Payments for property, plant and equipment 28 36
Proceeds from disposals of property, plant and equipment (31)
Payments for property, plant and equipment net of proceeds from disposals (3) 36
SUPPLEMENTAL INFORMATION ON NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL MEASURES
SPECIFIC ITEMS
The Corporation incurs some specific items that adversely or positively affect its operating results. We believe it is useful for readers to be aware of these items as they provide additional information to measure performance, compare the Corporation's results between periods, and assess operating results and liquidity, notwithstanding these specific items. Management believes these specific items are not necessarily reflective of the Corporation's underlying business operations in measuring and comparing its performance and analyzing future trends. Our definition of specific items may differ from that of other corporations and some of these items may arise in the future and may reduce the Corporation's available cash.
They include, but are not limited to, charges for (reversals of) impairment of assets, restructuring gains or costs, loss on refinancing and repurchase of long-term debt, some deferred tax asset provisions or reversals, premiums paid on repurchase of long-term debt, gains or losses on the acquisition or sale of a business unit, gains or losses on the share of results of associates and joint ventures, unrealized and realized gains or losses on derivative financial instruments that do not qualify for hedge accounting, unrealized gains or losses on interest rate hedge instruments and option fair value revaluation, foreign exchange gains or losses on long-term debt and financial instruments, fair value revaluation gains or losses on investments, specific items of discontinued operations and other significant items of an unusual, non-cash or non-recurring nature.
RECONCILIATION AND USES OF NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL MEASURES
To provide more information for evaluating the Corporation's performance, the financial information included in this analysis contains certain data that are not performance measures under IFRS Accounting Standards ("non-IFRS Accounting Standards measures"), which are also calculated on an adjusted basis to exclude specific items. We believe that providing certain key performance and capital measures, as well as non-IFRS Accounting Standards measures, is useful to both Management and investors, as they provide additional information to measure the performance and financial position of the Corporation. This also increases the transparency and clarity of the financial information. The following non-IFRS Accounting Standards measures and other financial measures are used in our financial disclosures:
Non-IFRS Accounting Standardsmeasures
- Adjusted earnings before interest, taxes, depreciation and amortization or EBITDA (A): represents the operating income (as published in the Consolidated Statements of Earnings (Loss) of the Consolidated Financial Statements) before depreciation and amortization excluding specific items. Measure used to assess recurring operating performance and the contribution of each segment on a comparable basis.
- Adjusted net earnings: Measure used to assess the Corporation's consolidated financial performance on a comparable basis.
- Adjusted cash flow: Measure used to assess the Corporation's capacity to generate cash flows to meet financial obligations and/or discretionary items such as share repurchases, dividend increases and strategic investments.
- Free cash flow: Measure used to calculate the excess cash the Corporation generates by subtracting capital expenditures (excluding strategic projects) from the EBITDA (A).
- Working capital: Measure used to assess the short-term liquidity of the Corporation.
Other financial measures
- Total debt: Measure used to calculate all the Corporation's debt, including long-term debt and bank loans. Often put in relation to equity to calculate the debt-to-equity ratio.
- Net debt: Measure used to calculate the Corporation's total debt less cash and cash equivalents. Often put in relation to EBITDA (A) to calculate the net debt to EBITDA (A) ratio.
Non-IFRS Accounting Standards ratios
- Net debt to EBITDA (A) ratio: Ratio used to assess the Corporation's ability to pay its debt and evaluate financial leverage.
- EBITDA (A) margin: Ratio used to assess operating performance and the contribution of each segment on a comparable basis calculated as a percentage of sales.
- Adjusted net earnings per common share: Ratio used to assess the Corporation's consolidated financial performance on a comparable basis.
- Ratio of net debt / (total equity and net debt): Ratio used to evaluate the Corporation's financial leverage and the risk to Shareholders.
- Working capital as a percentage of sales: Ratio used to assess the Corporation's operating liquidity performance.
- Adjusted cash flow per common share: Ratio used to assess the Corporation's financial flexibility.
- Free cash flow ratio: Ratio used to measure the liquidity and efficiency of how much more cash the Corporation generates than it uses to run the business by subtracting capital expenditures (excluding strategic projects) from the EBITDA (A) calculated as a percentage of sales.
Non-IFRS Accounting Standards measures and other financial measures are mainly derived from the consolidated financial statements, but do not have the meanings prescribed by IFRS Accounting Standards. These measures have limitations as an analytical tool and should not be considered on their own or as a substitute for an analysis of our results as reported under IFRS Accounting Standards. In addition, our definitions of non-IFRS Accounting Standards measures and other financial measures may differ from those of other corporations. Any such modification or reformulation may be significant.
The Corporation's operations are managed in two segments: Packaging Products and Tissue Papers.
The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)1). The CODM considers EBITDA (A)1 to be the best performance measure of the Corporation's activities.
EBITDA (A)1 by business segment is reconciled to the IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:
Q1 2026
(in millions of Canadian dollars) (unaudited) Packaging Tissue Papers Corporate, Consolidated
Products Recovery and
Recycling
activities
Operating income (loss) 88 20 (27) 81
Depreciation and amortization 49 13 9 71
Impairment charges 8 8
Other gain (47) (2) (49)
Restructuring costs 1 2 3
Loss on derivative financial instruments 4 4
EBITDA (A)
(1) 103 33 (18) 118
Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss) 568 327 50 945
Q4 2025
(in millions of Canadian dollars) (unaudited) Packaging Tissue Papers Corporate, Consolidated
Products Recovery and
Recycling
activities
Operating income (loss) 90 14 (28) 76
Depreciation and amortization 49 16 7 72
Impairment charges 11 12 2 25
Other gain (21) (21)
Restructuring costs 3 1 4
Gain on derivative financial instruments - (1) (1)
EBITDA (A)
(1) 132 42 (19) 155
Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss) 579 342 54 975
1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.
Q1 2025
(in millions of Canadian dollars) (unaudited) Packaging Tissue Papers Corporate, Consolidated
Products Recovery and
Recycling
activities
Operating income (loss) 60 24 (34) 50
Depreciation and amortization 46 13 10 69
Impairment charges - 1 1
Other loss 4 4
Restructuring costs 1 4 5
Gain on derivative financial instruments (2) (2) (4)
EBITDA (A)
(1) 109 37 (21) 125
Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss) 603 304 52 959
The following table reconciles net earnings and net earnings per common share, as reported, with adjusted net earnings1 and adjusted net earnings per common share1:
(in millions of Canadian dollars, except per common share amounts and number of NET EARNINGS NET EARNINGS
common shares) (unaudited)
PER COMMON SHARE
(2)
Q1 2026 Q4 2025 Q1 2025 Q1 2026 Q4 2025 Q1 2025
As reported 39 37 7 $0.38 $0.37 $0.07
Specific items:
Impairment charges 8 25 1 $0.06 $0.19 $0.01
Other loss (gain) (49) (21) 4 ($0.42) ($0.18) $0.03
Restructuring costs 3 4 5 $0.02 $0.03 $0.04
Loss (gain) on derivative financial instruments 4 (1) (4) $0.03 ($0.01) ($0.03)
Tax effect on specific items, other tax adjustments and attributable to non-controlling interest(2) 2 (4) $0.01
(32) 3 6 ($0.31) $0.03 $0.06
Adjusted
(1) 7 40 13 $0.07 $0.40 $0.13
Weighted average basic number of common shares outstanding 101,283,722 101,261,141 100,993,811
The following table reconciles cash flow from operating activities with EBITDA (A)1:
(in millions of Canadian dollars) (unaudited) Q1 2026 Q4 2025 Q1 2025
Cash flow from operating activities 18 183 (52)
Changes in non-cash working capital components 38 (33) 97
Net income taxes paid 4 1 2
Net financing expenses paid 52 16 49
Payments, net of provisions, for charges and other liabilities, and non-cash items, net of dividends received 6 (12) 29
EBITDA (A)
(1) 118 155 125
1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.
2 Specific amounts per common share are calculated on an after-tax basis and are net of the portion attributable to non-controlling interests. Per share amounts in line item ''Tax effect on specific items, other tax adjustments and attributable to non-controlling interests'' only include the effect of tax adjustments. Please refer to the "Provision for income taxes" section for more
details.
The following table reconciles cash flow from operating activities with cash flow from operating activities (excluding changes in non-cash working capital components) and adjusted cash flow from operating activities1. It also reconciles adjusted cash flow from operating activities1 to adjusted cash flow generated (used)1, which is also calculated on a per common share basis:
(in millions of Canadian dollars, except per common share amounts or otherwise noted) (unaudited) Q1 2026 Q4 2025 Q1 2025
Cash flow from operating activities 18 183 (52)
Changes in non-cash working capital components 38 (33) 97
Cash flow from operating activities (excluding changes in non-cash working capital components) 56 150 45
Restructuring costs paid 3 15 17
Adjusted cash flow from operating activities
(1) 59 165 62
Payments for property, plant and equipment (28) (42) (36)
Change in intangible and other assets (1) 1
Lease obligation payments (21) (19) (18)
9 104 9
Dividends paid to non-controlling interests (4) (4) (3)
Dividends paid to the Corporation's Shareholders and to non-controlling interests (12) (13) (12)
Adjusted cash flow generated (used)
(1) (7) 87 (6)
Adjusted cash flow generated (used) per common share
(1) ($0.07) $0.86 ($0.06)
(in Canadian dollars)
Weighted average basic number of common shares outstanding 101,283,722 101,261,141 100,993,811
The following table reconciles total debt1 and net debt1 with the ratio of net debt to adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A))1:
(in millions of Canadian dollars) (unaudited) March 31, December 31, March 31,
2026 2025 2025
Long-term debt 1,908 1,874 1,873
Current portion of unsecured senior notes 296
Current portion of long-term debt 78 70 72
Bank loans and advances 4
Total debt
(1) 1,986 1,944 2,245
Less: Cash and cash equivalents (85) (48) (29)
Net debt
(1)
as
reported 1,901 1,896 2,216
Last twelve months EBITDA (A)(1) 569 576 523
Net debt / EBITDA (A) ratio
(1) 3.3x 3.3x 4.2x
1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cascades-reports-results-for-the-first-quarter-of-2026-302764694.html
SOURCE Cascades Inc.
Media: Hugo D'Amours, Vice-President, Communications, Public Affairs and Sustainability, Cascades Inc., 819-363-5164, hugo_damours@cascades.com; Investors: Jennifer Aitken, MBA, Director, Investor Relations, Cascades Inc., 514-282-2697, jennifer_aitken@cascades.com; Source: Allan Hogg, Vice-President and Chief Financial Officer, Cascades Inc.